These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
416 related articles for article (PubMed ID: 24255004)
1. Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis. Dhillon S BioDrugs; 2014 Feb; 28(1):75-106. PubMed ID: 24255004 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice. Bouajina E; Zakraoui L; Kchir M; Kochbati S; Baklouti S Clin Rheumatol; 2020 May; 39(5):1449-1455. PubMed ID: 31838637 [TBL] [Abstract][Full Text] [Related]
3. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Oldfield V; Dhillon S; Plosker GL Drugs; 2009; 69(5):609-32. PubMed ID: 19368420 [TBL] [Abstract][Full Text] [Related]
4. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice. Bykerk VP; Östör AJ; Alvaro-Gracia J; Pavelka K; Román Ivorra JA; Graninger W; Bensen W; Nurmohamed MT; Krause A; Bernasconi C; Aassi M; Sibilia J Clin Rheumatol; 2015 Mar; 34(3):563-71. PubMed ID: 25604316 [TBL] [Abstract][Full Text] [Related]
5. Tocilizumab: A Review in Rheumatoid Arthritis. Scott LJ Drugs; 2017 Nov; 77(17):1865-1879. PubMed ID: 29094311 [TBL] [Abstract][Full Text] [Related]
6. Tocilizumab in patients with active rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs or tumor necrosis factor inhibitors: subanalysis of Spanish results of an open-label study close to clinical practice. Álvaro-Gracia JM; Fernández-Nebro A; García-López A; Guzmán M; Blanco FJ; Navarro FJ; Bustabad S; Armendáriz Y; Román-Ivorra JA; Reumatol Clin; 2014; 10(2):94-100. PubMed ID: 24099961 [TBL] [Abstract][Full Text] [Related]
7. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor. Abdulkader OAF; Qushmaq K; Aljishi F Ann Saudi Med; 2016; 36(3):190-6. PubMed ID: 27236390 [TBL] [Abstract][Full Text] [Related]
8. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. McLaughlin M; Östör A Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607 [TBL] [Abstract][Full Text] [Related]
10. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study. Weinblatt ME; Kremer J; Cush J; Rigby W; Teng LL; Devenport J; Singh N; Lepley D; Genovese MC Arthritis Care Res (Hoboken); 2013 Mar; 65(3):362-71. PubMed ID: 22972745 [TBL] [Abstract][Full Text] [Related]
11. Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis. Lamb YN; Deeks ED Drugs; 2018 Jun; 78(9):929-940. PubMed ID: 29931592 [TBL] [Abstract][Full Text] [Related]
12. Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis. Boyce EG; Rogan EL; Vyas D; Prasad N; Mai Y Ann Pharmacother; 2018 Aug; 52(8):780-791. PubMed ID: 29482351 [TBL] [Abstract][Full Text] [Related]
13. New biologics for rheumatoid arthritis. Choy E J R Coll Physicians Edinb; 2011 Sep; 41(3):234-7. PubMed ID: 21949922 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice. Punzi L; Lapadula G; Mathieu A BioDrugs; 2014 Apr; 28 Suppl 1():S25-37. PubMed ID: 24687236 [TBL] [Abstract][Full Text] [Related]
15. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial]. Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. Soini EJ; Hallinen TA; Puolakka K; Vihervaara V; Kauppi MJ J Med Econ; 2012; 15(2):340-51. PubMed ID: 22168785 [TBL] [Abstract][Full Text] [Related]
17. Biological agents in monotherapy for the treatment of rheumatoid arthritis. Gabay C; Hasler P; Kyburz D; So A; Villiger P; von Kempis J; Walker U Swiss Med Wkly; 2014; 144():w13950. PubMed ID: 24723273 [TBL] [Abstract][Full Text] [Related]
18. ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany. Iking-Konert C; von Hinüber U; Richter C; Schwenke H; Gürtler I; Kästner P; Klapperich B; Peters MA; Burmester GR Rheumatology (Oxford); 2016 Apr; 55(4):624-35. PubMed ID: 26515959 [TBL] [Abstract][Full Text] [Related]
19. Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study. Balsa A; Tovar Beltrán JV; Cáliz Cáliz R; Mateo Bernardo I; García-Vicuña R; Rodríguez-Gómez M; Belmonte Serrano MA; Marras C; Loza Cortina E; Pérez-Pampin E; Vila V Rheumatol Int; 2015 Sep; 35(9):1525-34. PubMed ID: 25773655 [TBL] [Abstract][Full Text] [Related]
20. Tocilizumab in the treatment of adult rheumatoid arthritis. Sanmartí R; Ruiz-Esquide V; Bastida C; Soy D Immunotherapy; 2018 Mar; 10(6):447-464. PubMed ID: 29495891 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]